Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using 89Zr-Trastuzumab PET: A Pilot Study

Melissa A. Lumish; Steven B. Maron; Viktoriya Paroder; Joanne F. Chou; Marinela Capanu; Steven Philemond; Joseph A. O’Donoghue; Heiko Schöder; Jason S. Lewis; Serge K. Lyashchenko; Neeta Pandit-Taskar; Yelena Y. Janjigian

doi:10.2967/jnumed.122.264470

Research ArticleClinical Investigation

Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using ⁸⁹Zr-Trastuzumab PET: A Pilot Study

Melissa A. Lumish, Steven B. Maron, Viktoriya Paroder, Joanne F. Chou, Marinela Capanu, Steven Philemond, Joseph A. O’Donoghue, Heiko Schöder, Jason S. Lewis, Serge K. Lyashchenko, Neeta Pandit-Taskar and Yelena Y. Janjigian

Journal of Nuclear Medicine May 2023, 64 (5) 724-730; DOI: https://doi.org/10.2967/jnumed.122.264470

Melissa A. Lumish

1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York;

2Department of Medicine, Weill Cornell Medical College, New York, New York;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Steven B. Maron

1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York;

2Department of Medicine, Weill Cornell Medical College, New York, New York;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Viktoriya Paroder

3Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Joanne F. Chou

4Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Marinela Capanu

4Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Steven Philemond

3Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Joseph A. O’Donoghue

5Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Heiko Schöder

6Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jason S. Lewis

3Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;

7Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York;

8Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, New York and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Serge K. Lyashchenko

7Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York;

8Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, New York and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Neeta Pandit-Taskar

3Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;

6Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York;

9Department of Radiology, Weill Cornell Medical College, New York, New York

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Yelena Y. Janjigian

1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York;

2Department of Medicine, Weill Cornell Medical College, New York, New York;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 64, Issue 5

May 1, 2023

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using 89Zr-Trastuzumab PET: A Pilot Study

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using ⁸⁹Zr-Trastuzumab PET: A Pilot Study

Journal of Nuclear Medicine May 2023, 64 (5) 724-730; DOI: 10.2967/jnumed.122.264470

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using ⁸⁹Zr-Trastuzumab PET: A Pilot Study

Journal of Nuclear Medicine May 2023, 64 (5) 724-730; DOI: 10.2967/jnumed.122.264470

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

18F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer
First-in-Human Evaluation of Site-Specifically Labeled 89Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer

Google Scholar

Keywords

HER2 heterogeneity
esophageal adenocarcinoma
gastric adenocarcinoma
trastuzumab
HER2 PET

Main menu

User menu

Search

Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using ⁸⁹Zr-Trastuzumab PET: A Pilot Study

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords